Literature DB >> 1528958

Bipolar illness, lithium prophylaxis, and pregnancy.

E M van Gent1, W M Verhoeven.   

Abstract

In advising bipolar patients wishing to become pregnant, Weinstein's guidelines were extended to seven stages: contraceptive measures; genetic counseling; discontinuing lithium in the first trimester or prescribing alternatives; ultrasound scanning for congenital anomalies, low lithium levels during pregnancy; discontinuing lithium at the end of pregnancy; starting immediately after birth, no breast feeding, observation of the neonate in the neonatal ward; and close observation of the patient in the follow-up year. Of the 15 bipolar patients, 11 gave birth to healthy children (five of them twice). Most patients knew nothing about the inheritance of bipolar illness. Four made no further attempt to become pregnant: two in view of a serious possibility of inheritance, the other two after a severe relapse. Three patients chose an alternative to lithium medication (carbamazepine and haloperidol). Postpartum, 27% of the patients who used medication relapsed and 60% of the patients who used none relapsed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1528958     DOI: 10.1055/s-2007-1014404

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  3 in total

Review 1.  Lithium Use and Non-use for Pregnant and Postpartum Women with Bipolar Disorder.

Authors:  Alison Hermann; Alyson Gorun; Abigail Benudis
Journal:  Curr Psychiatry Rep       Date:  2019-11-07       Impact factor: 5.285

2.  Bipolar disorder and psychotropic medication: Impact on pregnancy and neonatal outcomes.

Authors:  Katherine L Wisner; Dorothy Sit; Kelly O'Shea; Debra L Bogen; Crystal T Clark; Emily Pinheiro; Amy Yang; Jody D Ciolino
Journal:  J Affect Disord       Date:  2018-09-18       Impact factor: 4.839

Review 3.  Postpartum Relapse in Patients with Bipolar Disorder.

Authors:  Javier Conejo-Galindo; Alejandro Sanz-Giancola; Miguel Ángel Álvarez-Mon; Miguel Á Ortega; Luis Gutiérrez-Rojas; Guillermo Lahera
Journal:  J Clin Med       Date:  2022-07-08       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.